Frontotemporal dementia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TDP-43 4
• C9orf72 0
• MAPT 2
• TREM2 0
• CSF1R 0
• SOD1 0
• NRF2 0
• AKT 0
• APOE 0
• CDK4/6 0
• GLP-1 0
• HMGB1 0
• LRRK2 0
• MAPK 0
• NLRP3 0
• SIRT1 0
• SNCA 0
• STING 0
• TP53 0

EU-13 is a filter, not a ranking: it only narrows the list.

8 of 8+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies

  NCT07868328· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 4
• Mendelian Randomization Analysis 10
• CRISPR-Cas Systems 1
• Gene Expression Profiling 4
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 17
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 1
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 73
• Machine Learning 18
• Deep Learning 9
• Cohort Studies 34
• Genome-Wide Association Study 13

• Altered Membrane Protein Abundance in the Cerebral Cortex of the JNPL3 Mouse Model of Tauopathy.

  J Proteome Res, Oct 2026

• Integrative synaptosome multi-omics reveals disrupted synapse organization and localized cryptic transcripts in C9ORF72-frontotemporal dementia.

  Acta Neuropathol, Sept 2026

• Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration.

  Alzheimers Res Ther, Aug 2026

• Distinct proteomic CSF profiles in genetic frontotemporal lobar degeneration.

  Brain, Aug 2026

• Proteome-wide Mendelian randomization identifies causal plasma proteins in frontotemporal dementia.

  Neurol Sci, Jul 2026

• Plasma proteome profiling identified biomarkers for the differential diagnosis and molecular staging of neurodegenerative dementias.

  Nat Aging, Jul 2026

• Analytical and clinical validation of a novel proximity extension assay-based plasma biomarker panel in a cohort of prevalent neurodegenerative dementias.

  Alzheimers Res Ther, Jul 2026

• Plasma Proteomic Changes in GRN and C9orf72 Frontotemporal Dementia.

  Eur J Neurol, Jul 2026

• Dementia etiology classification using NULISA plasma biomarkers and machine learning.

  Alzheimers Dement, Jun 2026

• Proteomic analysis in Alzheimer's disease and other dementias: a focus on sex-specific differences.

  Alzheimers Res Ther, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.